The rationale for prophylactic cancer vaccines and need for a paradigm shift

Cancer Gene Therapy

Volumn 13, Issue 8, 2006, Pages 725-731

  Sobol, R E ^a  

^a Introgen Therapeutics Inc   (United States)

Author keywords

Cancer prevention; Cancer vaccines

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DNA VACCINE; DRUG VEHICLE; GLYCOLIPID; GLYCOPROTEIN; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; MELANOMA ANTIGEN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOPHENOL MONOOXYGENASE; ONCOFETAL ANTIGEN; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; RECOMBINANT AB INTERLEUKIN 2 FUSION PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; SMALLPOX VACCINE; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE;

ADENOMATOUS POLYP; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; BCG VACCINATION; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CANCER SURVIVAL; CARCINOMA; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COLON CANCER; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DATA ANALYSIS; DNA RECOMBINATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; EXPERIMENTAL ANIMAL; FAMILIAL POLYPOSIS; GENE DELETION; GENE MUTATION; GENETIC ENGINEERING; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOPROPHYLAXIS; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INFECTION; INTESTINE TUMOR; LEUKEMIA; LEUKEMIA REMISSION; LIVER CELL CARCINOMA; LYMPHOMA; MALIGNANT TRANSFORMATION; NASOPHARYNX CARCINOMA; NONHUMAN; ONCOGENE; PAPILLOMA; PNEUMONIA; POLIOMYELITIS; PRIORITY JOURNAL; RABIES; REVIEW; SMALLPOX; STREPTOCOCCUS INFECTION; SUICIDE GENE THERAPY; SUPERFICIAL CANCER; TRANSGENIC ANIMAL; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRAL GENE THERAPY; VIRUS CARCINOGENESIS; VIRUS RECOMBINANT;

ALGORITHMS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

ANIMALIA;

EID: 33746218253     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700950     Document Type: Review

References (60)

1. Dunn BK, Wickerham DL, Ford LG. Prevention of hormone-related cancers: breast cancer. J Clin Oncol 2005; 23: 357-367.
2. Parnes HL, Thompson IM, Ford LG. Prevention of hormone-related cancers: prostate cancer. J Clin Oncol 2005; 23: 368-377.
3. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol 2005; 23: 378-391.
4. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-2029.
5. Oettgen HF, Old LJ. History of cancer immunotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds). Biological Therapy of Cancer. JB Lippencott: Philadelphia, PA, 1991, pp 87-119.
6. Lamm DL. Efficacy and safety of bacille Calmette - Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000; 31(Suppl 3): S86-S90.
7. Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 2002; 29(3 Suppl 7): 18-26.
8. Rosenberg SA. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am 2000; 6(Suppl 1): S2-S7.
9. Levy R, Miller RA. Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. Annu Rev Med 1983; 34: 107-116.
10. Sobol RE, Dillman RO, Halpern S, Shawler DL, Hagan P, Ferrone S et al. Serotherapy and radioimmunodetection of tumors with monoclonal antibodies. In: Moloy P, Nicolson G (eds). Cellular Oncology: New Approaches in Biology, Diagnosis and Treatment. Praeger Press: New York, 1983, pp 256-281.
11. Levy R. A perspective on monoclonal antibody therapy: where we have been and where we are going. Semin Hematol 2000; 37(4 Suppl 7): 43-46.
12. Finn RS, Slamon DJ. Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif 2003; 21: 223-233.
13. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother 2003; 52: 342-346.
14. Lollini PL, Forni G. Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol Immunother 2002; 51: 409-416.
15. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3: 630-641.
16. Hellstrom KE, Hellstrom I. Novel approaches to therapeutic cancer vaccines. Expert Rev Vaccines 2003; 2: 517-532.
17. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004; 305: 200-205.
18. Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003; 13: 401-407.
19. Ragupathi G, Livingston P. The case for polyvalent cancer vaccines that induce antibodies. Expert Rev Vaccines 2002; 1: 193-206.
20. Herlyn D, Birebent B. Advances in cancer vaccine development. Ann Med 1999; 31: 66-78.
21. Whiteside TL, Vujanovic NL, Herberman RB. Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1998; 230: 221-244.
22. Dallai RM, Lotze MT. Immunotherapy of metastasis. Surg Oncol Clin N Am 2001; 10: 433-447.
23. Houghton AN, Guevara-Patino JA. Immune recognition of self in immunity against cancer. J Clin Invest 2004; 114: 468-471.
24. Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 2002; 99: 12275-12280.
25. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
26. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996; 93: 2909-2914.
27. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
28. Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 2002; 9: 464-469.
29. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003; 21: 2415-2432.
30. Nikitina EY, Chada S, Muro-Cacho C, Fang B, Zhang R, Roth JA et al. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Therapy 2002; 9: 345-352.
31. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995; 92: 11993-11997.
32. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004; 101(Suppl 2): 14631-14638.
33. Lam JS, Belldegrun AS, Figlin RA. Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther 2004; 4: 1081-1096.
34. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996; 93: 15388-15393.
35. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20: 125-133.
36. Maio M, Fonsatti E, Lamaj E, Altomonte M, Cattarossi I, Santantonio C et al. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 2002; 51: 9-14.
37. Farzaneh F, Habib N, Walden P. Cancer gene therapy: new horizons in the East International Society for Cancer Gene Therapy, Singapore, 20-22 February 2004. Cancer Immunol Immunother 2004; 53: 1052-1053.
38. Kawakami Y, Nishimura MI, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J et al. T-cell recognition of human melanoma antigens. J Immunother 1993; 14: 88-93.
39. Chen JJ, Saeki Y, Shi LF, Kohler H. Tumor idiotype vaccines. VI. Synergistic anti-tumor effects with combined 'internal image' anti-idiotypes and chemotherapy. J Immunol 1989; 143: 1053-1057.
40. Antonia S, Mule JJ, Weber JS. Current developments of immunotherapy in the clinic. Curr Opin Immunol 2004; 16: 130-136.
41. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611-618.
42. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003; 24: 335-342.
43. Mulryan K, Ryan MG, Myers KA, Shaw D, Wang W, Kingsman SM et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther 2002; 1: 1129-1137.
44. Dalgleish AG. Cancer vaccines as a therapeutic strategy. Expert Rev Vaccines 2004; 3: 665-668.
45. Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ et al. DNA vaccines to attack cancer. Proc Natl Acad Sci USA 2004; 101(Suppl 2): 14646-14652.
46. Henderson RA, Mossman S, Nairn N, Cheever MA. Cancer vaccines and immunotherapies: emerging perspectives. Vaccine 2005; 23: 2359-2362.
47. Dietzschold B, Ertl HC. New developments in the pre- and post-exposure treatment of rabies. Crit Rev Immunol 1991; 10: 427-439.
48. Jenner E. An inquiry into the causes and effects of the variolae vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow-pox. Sampson Low: Soho, London, 1798.
49. Gravitt PE, Shah KV. A Virus-based vaccine may prevent cervical cancer. Curr Infect Dis Rep 2005; 7: 125-131.
50. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23: 2388-2394.
51. Hilleman MR. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 2003; 21: 4626-4649.
52. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004; 16: 143-150.
53. De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A et al. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res 2004; 64: 4328-4337.
54. Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S et al. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 2003; 9: 1413-1417.
55. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002; 62: 6944-6951.
56. Zeytin HE, Patel AC, Rogers CJ, Canter D, Hursting SD, Schlom J et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res 2004; 64: 3668-3678.
57. Xiang R, Primus FJ, Ruehlmann JM, Niethammer AG, Silletti S, Lode HN et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 2001; 167: 4560-4565.
58. Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 2003; 100: 15101-15106.
59. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2004; 23: 276-292.
60. Greenwald P. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials. J Cell Biochem Suppl 1996; 25: 29-36.